{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T17:27:52Z","timestamp":1780766872707,"version":"3.54.1"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1126,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>The long-term outcome of patients with autoimmune hepatitis (AIH) in Japan has not been well-defined. The aim of this study was to clarify the outcome of this disease over a long follow-up period compared with that of the general Japanese population as well as that among patients. A total of 203 AIH patients were enrolled for a mean follow-up period of 131 months. All patients were treated with corticosteroids with or without azathioprine. The overall survival of AIH patients was similar to that of the general population in Japan. The prognosis of AIH subgroups divided according to disease severity, sex, incidence of relapse, liver histology, presence of cirrhosis, probable or definite AIH score, antibody to hepatitis B core antigen antibody positivity, or human leukocyte antigen DR4\u2013positivity did not differ greatly among patients. However, the prognosis of patients experiencing two or more relapses was significantly poorer than that of patients with remission or a single relapse both in univariate (<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>&lt; 0.001) and multivariate (<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 0.020) analyses. The development of liver malignancy was also a possibility among AIH patients with multiple relapses. Severe adverse effects of corticosteroids were rare, even in patients who underwent long-term treatment.<\/jats:bold>\n                                 <jats:bold>\n                                    Conclusion:\n                                 <\/jats:bold>\n                                 <jats:bold>Repeated relapses of AIH are significantly associated with a poorer long-term prognosis in Japan. AIH patients can expect a similar prognosis to that of the general population, provided they are adequately managed with continuous low doses of immunosuppressive therapy, especially after the first relapse. (HEPATOLOGY 2012)<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.25658","type":"journal-article","created":{"date-parts":[[2012,2,15]],"date-time":"2012-02-15T09:09:34Z","timestamp":1329296974000},"page":"668-676","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":99,"title":["Long-term outcome of Japanese patients with type 1 autoimmune hepatitis"],"prefix":"10.1097","volume":"56","author":[{"given":"Kaname","family":"Yoshizawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Ichijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeji","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Joshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiharu","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Katsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendo","family":"Kiyosawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morikazu","family":"Onji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-30-20241201","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1056\/NEJMra050408","article-title":"Autoimmune hepatitis.","volume":"354","author":"Krawitt","year":"2006","journal-title":"N Eng J Med"},{"key":"R2-30-20241201","doi-asserted-by":"crossref","first-page":"S132S144","DOI":"10.1002\/hep.21059","article-title":"Autoimmune hepatitis, from mechanisms to therapy.","volume":"43","author":"Manns","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R4-30-20241201","first-page":"735737","article-title":"Controlled trial of prednisone and azathioprine in active chronic hepatitis.","volume":"1","author":"MurrayLyon","year":"1973","journal-title":"Lancet"},{"key":"R5-30-20241201","doi-asserted-by":"crossref","first-page":"518523","DOI":"10.1016\/0016-5085(80)90866-5","article-title":"Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroidinduced remission.","volume":"78","author":"Czaja","year":"1980","journal-title":"Gastroenterology"},{"key":"R6-30-20241201","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1056\/NEJM198101013040102","article-title":"Corticosteroidtreated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis.","volume":"304","author":"Czaja","year":"1981","journal-title":"N Engl J Med"},{"key":"R7-30-20241201","doi-asserted-by":"crossref","first-page":"685689","DOI":"10.1002\/hep.1840030510","article-title":"Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis.","volume":"3","author":"Hegarty","year":"1983","journal-title":"HEPATOLOGY"},{"key":"R8-30-20241201","doi-asserted-by":"crossref","first-page":"215219","DOI":"10.1016\/0016-5085(87)90862-6","article-title":"Sustained remission after corticosteroid therapy of severe hepatitis B surface antigennegative chronic active hepatitis.","volume":"92","author":"Czaja","year":"1987","journal-title":"Gastroenterology"},{"key":"R9-30-20241201","doi-asserted-by":"crossref","first-page":"951957","DOI":"10.1016\/j.jhep.2005.06.006","article-title":"Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis.","volume":"43","author":"Miyake","year":"2005","journal-title":"J Hepatol"},{"key":"R10-30-20241201","first-page":"749755","article-title":"Predictive factors for remission and death in 73 patients with autoimmune hepatitis in Japan.","volume":"11","author":"Hino","year":"2003","journal-title":"Int J Mol Med"},{"key":"R11-30-20241201","doi-asserted-by":"crossref","first-page":"339348","DOI":"10.1055\/s-2001-13708","article-title":"Longterm management and prognosis of autoimmune hepatitis (AIH): a single center experience.","volume":"39","author":"Kanzler","year":"2001","journal-title":"Z Gastroenterol"},{"key":"R12-30-20241201","first-page":"507515","article-title":"Consequences of treatment withdrawal in type 1 autoimmune hepatitis.","volume":"27","author":"MontanoLoza","year":"2007","journal-title":"Liver Int"},{"key":"R13-30-20241201","doi-asserted-by":"crossref","first-page":"929938","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis report: review of criteria for diagnosis of autoimmune hepatitis.","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"R14-30-20241201","doi-asserted-by":"crossref","first-page":"284288","DOI":"10.1136\/gut.45.2.284","article-title":"High prevalence of antihepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan.","volume":"45","author":"Marusawa","year":"1999","journal-title":"Gut"},{"key":"R15-30-20241201","doi-asserted-by":"crossref","first-page":"289293","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C.","volume":"24","author":"Bedossa","year":"1996","journal-title":"HEPATOLOGY"},{"key":"R16-30-20241201","doi-asserted-by":"crossref","first-page":"19801989","DOI":"10.1053\/j.gastro.2011.02.065","article-title":"Longterm outocomes of patients with autoimmune hepatitis managed at a nontransplant center.","volume":"140","author":"Hoeroldt","year":"2011","journal-title":"Gastroenterology"},{"key":"R17-30-20241201","doi-asserted-by":"crossref","first-page":"848857","DOI":"10.1053\/gast.1996.v110.pm8608895","article-title":"Prognosis of histological cirrhosis in type 1 autoimmune hepatitis.","volume":"110","author":"Roberts","year":"1996","journal-title":"Gastroenterology"},{"key":"R18-30-20241201","doi-asserted-by":"crossref","first-page":"5362","DOI":"10.1002\/hep.20732","article-title":"Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome.","volume":"42","author":"Feld","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R19-30-20241201","first-page":"140147","article-title":"Impact of gender on the longterm outcome and survival of patients with autoimmune hepatitis.","volume":"48","author":"AlChalabi","year":"2008","journal-title":"J Hepatol"},{"key":"R20-30-20241201","doi-asserted-by":"crossref","first-page":"20512057","DOI":"10.1111\/j.1572-0241.2002.05921.x","article-title":"Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis.","volume":"97","author":"Czaja","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R21-30-20241201","doi-asserted-by":"crossref","first-page":"13001304","DOI":"10.1002\/hep.1840120609","article-title":"Association of autoimmune hepatitis with HLA Bw54 and DR4 in Japanese patients.","volume":"12","author":"Seki","year":"1990","journal-title":"HEPATOLOGY"},{"key":"R22-30-20241201","doi-asserted-by":"crossref","first-page":"10411047","DOI":"10.1016\/0016-5085(92)90041-V","article-title":"HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients.","volume":"103","author":"Seki","year":"1992","journal-title":"Gastroenterology"},{"key":"R23-30-20241201","doi-asserted-by":"crossref","first-page":"701706","DOI":"10.1002\/hep.1840130415","article-title":"Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1B8DR3 are independent risk factors.","volume":"13","author":"Donaldson","year":"1991","journal-title":"HEPATOLOGY"},{"key":"R24-30-20241201","doi-asserted-by":"crossref","first-page":"609615","DOI":"10.1002\/hep.1840190311","article-title":"Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis.","volume":"19","author":"Doherty","year":"1994","journal-title":"HEPATOLOGY"},{"key":"R25-30-20241201","doi-asserted-by":"crossref","first-page":"317323","DOI":"10.1002\/hep.510250211","article-title":"Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis.","volume":"25","author":"Czaja","year":"1997","journal-title":"HEPATOLOGY"},{"key":"R26-30-20241201","doi-asserted-by":"crossref","first-page":"578584","DOI":"10.1016\/j.jhep.2004.12.019","article-title":"Genetic analysis of the HLA region of Japanese patients with type 1 autoimmune hepatitis.","volume":"42","author":"Yoshizawa","year":"2005","journal-title":"J Hepatol"},{"key":"R28-30-20241201","doi-asserted-by":"crossref","first-page":"15021507","DOI":"10.1016\/0016-5085(93)90157-8","article-title":"Significance of HLA DR4 in type 1 autoimmune hepatitis.","volume":"105","author":"Czaja","year":"1993","journal-title":"Gastroenterology"},{"key":"R29-30-20241201","doi-asserted-by":"crossref","first-page":"384390","DOI":"10.1002\/hep.21518","article-title":"A genomewide DNA microsatellite association study of Japanese patients with autoimmune hepatitis type 1.","volume":"45","author":"Yokosawa","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R30-30-20241201","doi-asserted-by":"crossref","first-page":"578585","DOI":"10.1007\/s10620-010-1444-6","article-title":"Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series.","volume":"56","author":"Wong","year":"2011","journal-title":"Dig Dis Sci"},{"key":"R31-30-20241201","doi-asserted-by":"crossref","first-page":"863870","DOI":"10.1002\/hep.22432","article-title":"Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for followup and screening.","volume":"48","author":"Yeoman","year":"2008","journal-title":"HEPATOLOGY"},{"key":"R32-30-20241201","doi-asserted-by":"crossref","first-page":"114117","DOI":"10.1007\/s12029-008-9040-0","article-title":"Cholangiocarcinoma: expanding the spectrum of risk factors.","volume":"39","author":"Elfaki","year":"2008","journal-title":"J Gastrointest Cancer"},{"key":"R33-30-20241201","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1159\/000268467","article-title":"Large intrahepatic cholangiocarcinoma with tumor infiltrative lymphocytes and autoimmune hepatitislike features.","volume":"4","author":"Izumi","year":"2010","journal-title":"Case Rep Gastroenterol"},{"key":"R34-30-20241201","doi-asserted-by":"crossref","first-page":"404407","DOI":"10.4253\/wjge.v2.i12.404","article-title":"Use of endoscopic ultrasound for diagnosis of cholangiocarcinoma in autoimmune hepatitis.","volume":"2","author":"Rial","year":"2010","journal-title":"World J Gastrointest Endosc"},{"key":"R35-30-20241201","doi-asserted-by":"crossref","first-page":"12101218","DOI":"10.1016\/j.jhep.2009.01.020","article-title":"Autoimmune hepatitis in Italy: the Bologna experience.","volume":"50","author":"Muratori","year":"2009","journal-title":"J Hepatol"},{"key":"R36-30-20241201","doi-asserted-by":"crossref","first-page":"18741875","DOI":"10.1053\/j.gastro.2011.04.026","article-title":"Autoimmune hepatitis: the dilemma of rare disease.","volume":"140","author":"Manns","year":"2011","journal-title":"Gastroenterology"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.25658","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201208000-00030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T14:06:52Z","timestamp":1733062012000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201208000-00030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.25658","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}